Overview

Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well bortezomib works in treating patients with stage IIIB or stage IV lung cancer. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Bortezomib